Johnson & Johnson

Latest Headlines

Latest Headlines

J&J partners with startup for DNA vaccine, hand-held device to treat HBV in $85M+ deal

Janssen Pharmaceuticals has paired up with Ichor Medical Systems to develop and market DNA-based vaccine products to treat chronic hepatitis B. The partners will use the startup's TriGrid electroporation technology for clinical administration of a DNA vaccine.

Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO

A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.

J&J's Ethicon gets FDA clearance to use Evarrest patch for liver surgery

Johnson & Johnson's Ethicon division received clearance from the FDA for an expanded indication of its Evarrest patch, which can now be used to help control bleeding during adult liver surgery.

Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.

Goal of J&J's pro soccer marketing deal? Scoring with millennials, Hispanics

Johnson & Johnson's consumer division knows that much of its target audience consists of millennials, Hispanics and moms--and that those three groups have something else in common, too: soccer.

Forget fighting over Flonase ads. GSK and J&J settle on fight for market share

GlaxoSmithKline and Johnson & Johnson have settled a short-lived legal spat over GSK's allergy drug marketing claims--meaning that now, the only battle left will be the one for market share.

Google, J&J partner to advance surgical robotics

Johnson & Johnson and Google have partnered to create new robotic-assisted surgical platforms. The deal is the latest example of Google working with a major life sciences company to make a significant technological advance.

J&J CEO Gorsky sees 'new horizon' in China, despite slowing growth

Johnson & Johnson has a Chinese strategy: long-term thinking. Despite an economic slowdown and regulatory crackdowns--and the example of other multinationals that have scaled back there--CEO Alex Gorsky figures it's worth it to ride out the storm.

J&J, Philips partner to develop hand-held blood test for neuropsychiatric disorders

Royal Philips and Janssen Pharmaceutical have partnered in a multiyear deal to create a hand-held, blood-based diagnostic for brain disorders. The test will be based on a product that Philips is already developing, the Minicare system. The financial details of the partnership were undisclosed.

Psoriasis data wars heat up at AAD with Novartis, Boehringer studies

Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.